GSK Still Waiting For Infectious Disease Strategy To Move The Needle
Arexvy Set To Lead RSV Field, But Investors Want More
Ongoing Zantac litigation continues to cloud GSK’s share price, but it hopes a stream of infectious disease readouts will sway investor sentiment as it prepares for Arexvy’s launch.
